[go: up one dir, main page]

JP2011508768A - パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤 - Google Patents

パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤 Download PDF

Info

Publication number
JP2011508768A
JP2011508768A JP2010541104A JP2010541104A JP2011508768A JP 2011508768 A JP2011508768 A JP 2011508768A JP 2010541104 A JP2010541104 A JP 2010541104A JP 2010541104 A JP2010541104 A JP 2010541104A JP 2011508768 A JP2011508768 A JP 2011508768A
Authority
JP
Japan
Prior art keywords
suspension
pharmaceutical
oral
sodium
ibuprofen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010541104A
Other languages
English (en)
Japanese (ja)
Inventor
アトキンソン，ハートレー
カイリー，オースティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFT Pharmaceuticals Ltd
Original Assignee
AFT Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFT Pharmaceuticals Ltd filed Critical AFT Pharmaceuticals Ltd
Publication of JP2011508768A publication Critical patent/JP2011508768A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2010541104A 2008-01-03 2008-01-03 パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤 Pending JP2011508768A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2008/000005 WO2009083759A1 (en) 2008-01-03 2008-01-03 Oral pharmaceutical suspension comprising paracetamol and ibuprofen

Publications (1)

Publication Number Publication Date
JP2011508768A true JP2011508768A (ja) 2011-03-17

Family

ID=39521691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010541104A Pending JP2011508768A (ja) 2008-01-03 2008-01-03 パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤

Country Status (12)

Country Link
US (1) US20110124730A1 (es)
EP (1) EP2231138A1 (es)
JP (1) JP2011508768A (es)
KR (1) KR20110065417A (es)
CN (1) CN102006867A (es)
AU (1) AU2008345456A1 (es)
BR (1) BRPI0821871A2 (es)
CA (1) CA2711211A1 (es)
MA (1) MA32056B1 (es)
MX (1) MX2010007358A (es)
WO (1) WO2009083759A1 (es)
ZA (1) ZA201004650B (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
JP2017522382A (ja) * 2014-07-18 2017-08-10 エバーブライト ファーマシューティカルズ エス．エー．アール．エル． パラセタモール及びイブプロフェンを含む水性配合物
JP2018158928A (ja) * 2018-05-25 2018-10-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
US11413241B2 (en) 2017-04-20 2022-08-16 Hyloris Developments Sa Method for preparing a composition with a low dissolved oxygen content, comprising acetaminophen, and optionally one or more NSAIDs, and a composition obtained thereof
JP2023508085A (ja) * 2019-12-23 2023-02-28 ヌトラ、エッセンシャル、オテセ、ソシエダッド、リミターダ イブプロフェンおよびフェニレフリンを含んでなる液体組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448499A (zh) * 2009-04-27 2012-05-09 药效学应用实验室股份有限公司 赖氨酸布洛芬口服混悬剂
CN101991531B (zh) * 2010-11-09 2012-06-27 武汉人福药业有限责任公司 布洛芬口服混悬液及其制备方法
EP2744481A4 (en) * 2011-08-16 2015-07-01 Merck Sharp & Dohme USE OF COMBINATIONS OF AN INORGANIC MATRIX AND AN ORGANIC POLYMER FOR THE MANUFACTURE OF STABLE AMOUNT DISPERSIONS
FR2999934B1 (fr) * 2012-12-21 2015-02-20 Servier Lab Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane
WO2014102802A1 (en) * 2012-12-30 2014-07-03 Hadasit Medical Research Services And Development Ltd. Alginate compositions and uses thereof
CN103961312A (zh) * 2014-05-26 2014-08-06 王学重 一种扑热息痛口服液及其制备方法
DE102016203146A1 (de) 2016-02-26 2017-08-31 Ivoclar Vivadent Ag Antibakterielle Mundpflegegele
CN106361695B (zh) * 2016-08-26 2017-12-19 湖北唯森制药有限公司 一种右旋布洛芬的研磨方法及其混悬液的制备方法
CN111031996B (zh) * 2017-07-10 2022-04-15 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
CN111787916B (zh) * 2018-01-11 2023-09-05 森陶鲁斯治疗公司 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂
KR101926853B1 (ko) * 2018-04-13 2018-12-07 보령제약 주식회사 약학적 조성물
KR102145022B1 (ko) * 2018-08-14 2020-08-14 동아제약 주식회사 이부프로펜의 현탁액 조성물 및 투여 제형
US11969400B2 (en) * 2021-03-23 2024-04-30 Kumara V. Nibhanipudi Ibuprofen for symptomatic treatment of diarrheas in HIV patients
WO2023129946A1 (en) * 2021-12-28 2023-07-06 Zonfrillo Mark Robert Methods and kits for treating fever in children with combined ibuprofen and acetaminophen
CN121285367A (zh) 2023-06-02 2026-01-06 尤利亚·采蒂 包含布洛芬的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069033A2 (en) * 2005-12-12 2007-06-21 Adcock Ingram Limited Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0109281A1 (en) * 1982-11-15 1984-05-23 The Upjohn Company Compositions comprising flurbiprofen or ibuprofen
US4788220A (en) * 1987-07-08 1988-11-29 American Home Products Corporation (Del.) Pediatric ibuprofen compositions
NZ234143A (en) * 1989-06-28 1991-10-25 Mcneil Ppc Inc Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5712310A (en) * 1996-06-14 1998-01-27 Alpharma Uspd, Inc. Suspension of substantially water-insoluble drugs and methods of their manufacture
BRPI0512756A (pt) * 2004-07-07 2008-04-08 Aft Pharmaceuticals Ltd composição farmacêutica de combinação para o tratamento de dor, método de controle de dor, uso de uma composição e embalagem farmacêutica incluindo comprimidos ou cápsulas
EP3292866B1 (en) * 2006-10-20 2023-07-26 Johnson & Johnson Consumer Inc. Acetaminophen / ibuprofen combinations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069033A2 (en) * 2005-12-12 2007-06-21 Adcock Ingram Limited Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016520100A (ja) * 2013-11-13 2016-07-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
JP2017522382A (ja) * 2014-07-18 2017-08-10 エバーブライト ファーマシューティカルズ エス．エー．アール．エル． パラセタモール及びイブプロフェンを含む水性配合物
JP2020059740A (ja) * 2014-07-18 2020-04-16 エバーブライト ファーマシューティカルズ エス．エー．アール．エル． パラセタモール及びイブプロフェンを含む水性配合物
US11213498B2 (en) 2014-07-18 2022-01-04 Hyloris Pharmaceuticals S.A. Aqueous formulation comprising paracetamol and ibuprofen
US11219609B2 (en) 2014-07-18 2022-01-11 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
US11389416B2 (en) 2014-07-18 2022-07-19 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
US12083087B2 (en) 2014-07-18 2024-09-10 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
US11413241B2 (en) 2017-04-20 2022-08-16 Hyloris Developments Sa Method for preparing a composition with a low dissolved oxygen content, comprising acetaminophen, and optionally one or more NSAIDs, and a composition obtained thereof
JP2018158928A (ja) * 2018-05-25 2018-10-11 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
JP2023508085A (ja) * 2019-12-23 2023-02-28 ヌトラ、エッセンシャル、オテセ、ソシエダッド、リミターダ イブプロフェンおよびフェニレフリンを含んでなる液体組成物
JP7614207B2 (ja) 2019-12-23 2025-01-15 ヌトラ、エッセンシャル、オテセ、ソシエダッド、リミターダ イブプロフェンおよびフェニレフリンを含んでなる液体組成物

Also Published As

Publication number Publication date
ZA201004650B (en) 2011-09-28
MX2010007358A (es) 2011-05-25
KR20110065417A (ko) 2011-06-15
BRPI0821871A2 (pt) 2015-06-16
WO2009083759A1 (en) 2009-07-09
EP2231138A1 (en) 2010-09-29
CA2711211A1 (en) 2009-07-09
MA32056B1 (fr) 2011-02-01
CN102006867A (zh) 2011-04-06
AU2008345456A1 (en) 2009-07-09
US20110124730A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
JP2011508768A (ja) パラセタモール及びイブプロフェンを含む医薬用経口懸濁剤
CA2567075C (en) Pharmaceutical suspension composition
JP6273589B2 (ja) 安定化されたカリスバメートの小児用懸濁液
JP2009543777A (ja) 安定性を増強したフェニレフリン液体組成物
JP2012505172A (ja) パラセタモールを有する液体医薬製剤
ES2266828T3 (es) Sales de tolterodina.
CN101854913A (zh) 含有缬沙坦的液体组合物
US20090048344A1 (en) Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
JP2005015479A (ja) 局所麻酔薬を含有する口中用または咽頭部用製剤
CN1468096A (zh) 莫达非尼化合物的药用溶液
JP2007022941A (ja) ゲル状経口製剤
US20080085892A1 (en) Liquid dosage form of acetaminophen
WO2004030673A1 (ja) 経口吸収性が改善された抗菌性医薬組成物
CN103751158A (zh) 含有扑热息痛和布洛芬的口服药物混悬剂
TW201038296A (en) Ibuprofen lysinate oral suspension
US20070219253A1 (en) Decongestant / antihistaminic / expectorant compositions
WO2021021055A1 (en) Combination of oxolamine and terbutaline
ITBO20100731A1 (it) Composizioni solide comprendenti antiinfiammatori non steroidei, processi per la loro preparazione e loro uso.
HK1086492B (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluoroanilino)phenylacetic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121023

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130319